Ironwood Terminated Rights of Zurampic lesinurad and Duzallo lesinurad/allopurinol Deal with AZ

 Ironwood Terminated Rights of Zurampic lesinurad and Duzallo lesinurad/allopurinol Deal with AZ

Ironwood Terminated Rights of Zurampic lesinurad and Duzallo lesinurad/allopurinol Deal with AZ

Shots:
  •   As per Ironwood Zurampic generated $1.1Mn in 2Q18 and $3.1 Mn in 2017, company to reduce 125 field sales employees
  • This termination agreement is expected to save $75-$100Mn in FY19 expenses
  •  This deal was executed in 2016 with Ironwood paying $100Mn upfront followed by $15Mn milestone payment post approval in US along with single-digit royalties  
Click here to read full press release/ article | Ref: Biocentury | Image: Forbes

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post